Recordati Rare Diseases News and Activities

Recordati Rare Diseases is owned by Recordati.

Recordati is one of the...

• Stoxx 600;
• TOB Iconic 10,000.

Recordati is a company listed under the stock ticker REC (IT).

Recordati has a direct presence in 5 countries.

Recordati has 4 subsidiaries including Opalia Pharma, Recordati Ireland & UK and Recordati Pharma Turkey.

They are in:

• Pharmaceuticals80%
• Biotechnology20%

Acquisition, funding and merger involving Recordati.

• CVC Capital Partners has announced the acquisition of Recordati  (posted on May 26 2026).

View the org chart displaying its 15 main executives

Most searched biographies at Recordati Rare Diseases

• Scott Pescatore, Executive Vice President
• Juan Vila Alvarez, Vice President, European Rare Diseases, North, ...
• Mohamed Ladha, President and General Manager, North America

Popular executive movements at Recordati

• Daniel Bastiaans, Vice President of Global Total Rewards, has left the company  (posted on January 9 2026).
• Attilio Benedetto, Head of Procurement Pharmaceutical Packaging Materials, has left the company  (posted on November 6 2025).
• Angela Tuozzi, who was Production Manager, is promoted to Production Director, Campoverde  (posted on November 5 2025).

Click here to view some more movements at Recordati

Create your alert
to follow the executive moves at Recordati Rare Diseases.

Recordati has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Recordati Rare Diseases

• RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
• RECORDATI COMPLETES THE ACQUISITION OF THE GLOBAL RIGHTS TO ENJAYMO®
• RECORDATI COMPLETES THE ACQUISITION OF THE GLOBAL RIGHTS TO ENJAYMO®
• RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Social media about Recordati Rare Diseases

• Recordati Rare Diseases on Wikipedia, Google News & Yahoo Finance
• Recordati Rare Diseases on LinkedIn, X (Twitter) & YouTube